Compare Genuine Parts Company (GPC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs IDEXX Laboratories, Inc. — how do they compare? Genuine Parts Company trades at $133.43 (market cap $18.62B), while IDEXX Laboratories, Inc. trades at $571.3 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.5× Genuine Parts Company's market cap, and Genuine Parts Company pays a 3.15% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GPC | IDXX | |
|---|---|---|
Market Cap | $18.62B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $766.68 |
52-Week Low | $92.47 | $526.44 |
Enterprise Value | $24.72B | $47.12B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $133.47, down 0.8% today, with a bullish technical trend and strong institutional support. Recent Q2 2026 earnings beat estimates with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The stock is near its 52-week high, supported by a consensus price target of $148.67, though net income margins remain thin at 0.13%.
Outlook is positive with analyst consensus leaning buy, but risks include compressed profitability and high P/E ratio. The dividend yield adds income appeal, yet margin pressures from inflation and competition warrant caution for growth-focused investors.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
